Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity is a research paper published in Cancer Immunology Immunotherapy (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 3P30CA240139-02S3
The Sylvester Cancer Center Support Grant
National Institutes of Health
Grant: 1R21CA195334-01A1
A novel IL-2 biologic and tumor immunity
NCI NIH HHS
Grant: P30 CA240139
NCI NIH HHS
Grant: R21 CA195334
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals